AGMB logo

AGOMAB THERAPEUTICS NV

AGMBNASDAQ
🏆 #2961 by market capUS Equity
$10.51▲ $0.43 (+4.06%)
Market closed · at close
🔔
Track AGMB
Get earnings, price moves & breaking news on Telegram
Track
24h▲ 4.1%
7d▼ 2.3%
14d▼ 7.6%
30d▼ 19.2%
ytd—
1y—
🏦Market Cap
$518M
Small Cap
📈Revenue Growth (YoY)
+0.0%
Slowing
📊Gross Margin
0.0%
Thin
💵FCF Margin
0.0%
Thin
⚖️P/S Ratio
0.0x
Cheap
Otter Score
64
Fair

Trading Snapshot

Day Range
$10.40 – $10.68
52-Week Range
$8.75 – $17.82
Volume
$4.85B
Avg Volume
$5.79B
Shares Outstanding
49.2M
Next Earnings
Nov 14, 2026

Fundamentals Snapshot

Annual Revenue
$120M
Last Q Revenue
$33M
P/E Ratio
-11.4
P/S Ratio
0.0x
EPS (TTM)
$-0.73
Dividend Yield
0.00%
Dilution (1yr)
+34.5%

Why Investors Own AGMB

  • ✓High-growth profile — revenue up -4.0% YoY with expanding US Equity exposure.
  • ✓Healthy economics — 74% gross margin and 26% free-cash-flow margin.
  • ✓New products and segments could unlock additional revenue streams.
⚠️ Key Risks

Execution delays, intensifying competition, and valuation compression if growth decelerates.

AGMB logo

AGOMAB THERAPEUTICS NV

AGMB
Financial Trends
RevenueThe total money the company brought in from sales, before subtracting any costs.
$0▲ +0.0% YoY
Operating IncomeProfit from the core business after operating costs, but before interest and taxes. Negative means the core business isn’t profitable yet.
−$59M▲ +23.4% YoY
Shares OutstandingHow many shares exist. Rising means the company is issuing more shares, which dilutes (shrinks) each existing owner’s slice.
48.7M▲ +34.5% YoY
Net CashCash minus total debt. Positive = more cash than debt (financially strong); negative = more debt than cash (net debt).
$85M▼ −$85M YoY
StockOtter · stockotter.space

About AGOMAB THERAPEUTICS NV

AgomAb Therapeutics N.V. is a clinical-stage biopharmaceutical company dedicated to developing novel, disease-modifying therapies. Its primary focus lies in immunology and inflammatory ailments, particularly chronic fibrotic conditions where significant unmet medical needs persist. Its innovative pipeline features several promising candidates, including Ontunisertib (AGMB-129), an orally administered, gastrointestinal-restricted small molecule inhibitor targeting ALK5 or TGFßR1, designed to treat Fibrostenosing Crohn's disease and presently undergoing Phase 2a clinical trials. Also in development is AGMB-447, an inhaled small molecule that similarly inhibits ALK5 or TGFßR1, intended for idiopathic pulmonary fibrosis and currently in Phase 1 clinical studies. Furthermore, the company is advancing AGMB-101, a monoclonal antibody designed to mimic HGF. This agent exerts its effects through the agonism or stimulation of the MET receptor, having demonstrated both antifibrotic and regenerative capabilities in preclinical models. Established in 2017, AgomAb Therapeutics maintains its headquarters in Antwerp, Belgium.

🦦

Otter Score Breakdown

How it's scoredFive components, each rated 1–5★ and equally weighted (20%), averaged to a 0–100 score:💎 Quality — gross margin🚀 Growth — revenue YoY⚖️ Valuation — P/S ratio⚡ Momentum — 30-day price change💧 Dilution — 1-yr share issuance (buybacks score higher)
💎Quality★★★★★
🚀Growth★★★★★
⚖️Valuation★★★★★
⚡Momentum★★★★★
💧Dilution★★★★★
Overall Score
Fair
64/100

Analyst Price Target

ⓘ
Average Target
$13.41
▲ +27.6% Upside
High Target$15.16
Low Target$12.02
Based on 16 analysts

Latest News & Updates

🚀
CNBC·2h ago

AGOMAB THERAPEUTICS NV tops quarterly estimates as demand accelerates

Revenue grew double digits with management guiding above consensus; margins continued to expand.

🛰️
CNBC·5h ago

Analysts lift AGMB price targets on improving margins

Several firms raised targets, citing stronger free cash flow and a healthier backlog.

🌌
CNBC·1d ago

AGOMAB THERAPEUTICS NV announces new agreement to expand its footprint

The move broadens the company’s reach and could add incremental revenue over the next year.